Niktimvo is approved for treatment of chronic graft-versus-host disease. Incyte and its partner developer forecast that it may earn $650 million in net profit.
AstraZeneca has announced it will invest millions in one of its state-of-the-art facilities that focuses on packing protein therapeutics in a growing area in its portfolio.
Hervé Hoppenot, president and CEO of Delaware’s pioneering biopharmaceutical company Incyte who has helped guide the company to new heights, has been named the 2024 Pete du Pont Freedom Award honoree.
WILMINGTON — Corteva was awarded the go-ahead by a Delaware federal court to continue a lawsuit against Inari Agriculture, citing alleged intellectual property law and patent violations. Originally filed last […]
In 2014, Ashland sold its water division for $1.8 billion; a decade later, the remnants, now Solenis, are valued at $8 billion, operating in 120 countries.
Prelude Therapeutics has now signed its second deal in two years, and this time, it's with $60 billion pharmaceutical company Merck.
Delaware was one of three states that joined together in the bid for the PROPEL Tech Hub, seeking close to $80 million to boost the region’s relevance in precision medicine.
When the EastSide Charter School community STEM facility opens in the next couple months, it will feature a new program set to train adults in biomanufacturing and basic lab functions.
AstraZeneca has recently completed a $2.4 billion deal for a California-based pharmaceutical company that gives the company a boost in next-generation cancer treatments.
Precision medicine in Delaware is part of a larger picture of revolutionizing treatment for every body, according to its genetic makeup.
Premier Digital Partners
© 2024 Delaware Business Times
